|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024419,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0092801,
umls-concept:C0205195,
umls-concept:C0205210,
umls-concept:C0205390,
umls-concept:C0205460,
umls-concept:C0393022,
umls-concept:C0443315,
umls-concept:C1096776,
umls-concept:C1274040
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2010-4-30
|
|
pubmed:abstractText |
To assess the efficacy of 2-chloro-2'-deoxyadenosine (2-CdA) given subcutaneously (SC) in combination with rituximab in the treatment of newly diagnosed/pretreated patients with Waldenström macroglobulinemia (WM) and to correlate the response to treatment with biologic findings (immunophenotypic and pharmacogenomic analysis).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Cladribine,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Transport Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/ZAP-70 Protein-Tyrosine Kinase,
http://linkedlifedata.com/resource/pubmed/chemical/ZAP70 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/cif nucleoside transporter,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AndreolaGiovannaG,
pubmed-author:BertoliniFrancescoF,
pubmed-author:BillioAttoA,
pubmed-author:CalabreseLilianaL,
pubmed-author:FabbriAlbertoA,
pubmed-author:FrigeriFerdinandoF,
pubmed-author:LaszloDanieleD,
pubmed-author:MancusoPatriziaP,
pubmed-author:MartinelliGiovanniG,
pubmed-author:PintoAntonelloA,
pubmed-author:PruneriGiancarloG,
pubmed-author:RabascioCristinaC,
pubmed-author:RadiceDavideD,
pubmed-author:RigacciLuigiL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2233-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20368573-Adult,
pubmed-meshheading:20368573-Aged,
pubmed-meshheading:20368573-Antibodies, Monoclonal,
pubmed-meshheading:20368573-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20368573-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20368573-Cladribine,
pubmed-meshheading:20368573-Disease-Free Survival,
pubmed-meshheading:20368573-Drug Administration Schedule,
pubmed-meshheading:20368573-Female,
pubmed-meshheading:20368573-Genotype,
pubmed-meshheading:20368573-Humans,
pubmed-meshheading:20368573-Immunophenotyping,
pubmed-meshheading:20368573-Injections, Subcutaneous,
pubmed-meshheading:20368573-Italy,
pubmed-meshheading:20368573-Kaplan-Meier Estimate,
pubmed-meshheading:20368573-Male,
pubmed-meshheading:20368573-Membrane Transport Proteins,
pubmed-meshheading:20368573-Middle Aged,
pubmed-meshheading:20368573-Patient Selection,
pubmed-meshheading:20368573-Phenotype,
pubmed-meshheading:20368573-Prospective Studies,
pubmed-meshheading:20368573-Time Factors,
pubmed-meshheading:20368573-Treatment Outcome,
pubmed-meshheading:20368573-Waldenstrom Macroglobulinemia,
pubmed-meshheading:20368573-ZAP-70 Protein-Tyrosine Kinase
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
|
|
pubmed:affiliation |
Department of Hematology, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy. daniele.laszlo@ieo.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
